BBernstein AArm · ARM

Bernstein SocGen Raises Arm Holdings Price Target to $500

Jun 17, 2026· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$500
Previous
$300
Implied upside
+26%

Bernstein SocGen Group analyst David Dai raised the price target on Arm Holdings (NASDAQ: ARM) to $500.00 (from $300.00) while maintaining an Outperform rating.

“Raising Arm PT to $500, as Arm is the structural beneficiary of the renaissance of CPUs for agentic AI. Arm architecture is suitable for agentic AI workload given its unparalleled power efficiency.

In addition, Arm is shifting from just IP provider to CPU maker, aiming to capture $15bn revenue by CY2030, but we now forecast $22bn as we revise CPU TAM to $223bn in 2030 (from $137bn).

Arm’s 2030 EPS (FYE31) is now lifted to $11.79 ($9.83 prior).

Based on 42x P/E (40x prior), we lift Arm’s PT to $500 (21% upside).

Given the lifted PT of Arm, we also raise SoftBank PT to ¥11,200 (58% upside), based on 30% discount to pro-forma NAV of $572bn.”

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.